Fixed-dose compounds and the secondary prevention of ischemic heart disease;Compuestos de dosis fija en la prevención secundaria de la cardiopatía isquémica

Revista Espanola de Cardiologia

Volumn 64, Issue SUPPL. 2, 2011, Pages 3-9

  Fuster, Valentín ^a,b   Sanz, Ginés ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Ischemic heart disease; Polypill; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; COMBINATION CHEMOTHERAPY; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY;

CARDIOVASCULAR AGENTS; DRUG COMBINATIONS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; SECONDARY PREVENTION;

EID: 79961121938     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.02.027     Document Type: Article

References (17)

1. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3. (Pubitemid 34756482)
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
4. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330:1059-63. (Pubitemid 40646559)
5. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581-8. (Pubitemid 44209181)
6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-9. (Pubitemid 47176510)
7. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2009;53:1326-37.
8. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-40.
9. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-37.
10. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six lowand middle-income countries. Bull World Health Organ. 2007;85:279-88. (Pubitemid 46556727)
11. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus componentbased free-combination therapy. Am J Cardiovasc Drugs. 2008;8: 45-50. (Pubitemid 351311519)
12. Fuster V, Voute J, Hunn M, Smith SC Jr. Low priority of cardiovascular and chronic diseases on the global health agenda: a cause for concern. Circulation. 2007;116:1966-70. (Pubitemid 350287092)
13. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heartdisease and stroke statistics -2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151.
14. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med. 2009;6:112-9.
15. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-51.
16. Fuster V, Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med. 2007;4:173. (Pubitemid 46502085)
17. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009;6:101-10.